GSK Ships Experimental Ebola Vaccine To Liberia; Trial Of 2 Vaccine Candidates To Begin There Soon
BBC News: Ebola crisis: Experimental vaccine ‘shipped to Liberia’
“The first batch of an experimental vaccine against Ebola is on its way to Liberia. The shipment will be the first potentially preventative medicine to reach one of the hardest hit countries…” (Mundasad, 1/23).
CQ HealthBeat: Top Ebola Vaccine Candidates to Be Tested in Same Trial
“…A three-pronged trial will involve a vaccine developed by the National Institutes of Allergy and Infectious Diseases and GlaxoSmithKline Plc and one that is being developed by Merck & Co. and New Link Genetics. People participating in the test will be randomly assigned to get either one of the vaccines or a placebo…” (Young, 1/22).
Financial Times: GSK ships Ebola vaccine to West Africa
“…International health authorities are scrambling to launch trials while there are still enough cases to produce evidence that the GSK vaccine and another from U.S.-based Merck & Co are effective…” (Ward, 1/23).
The Guardian: Experimental Ebola vaccine shipped to Liberia
“…Health care workers and others at high risk from Ebola in Liberia could be given an experimental vaccine as early as next week following the shipment of the first doses to Monrovia, according to the manufacturer GlaxoSmithKline…” (Boseley, 1/23).
New York Times: Trial of 2 Ebola Vaccines’ Effectiveness Is Announced
“…The number of new Ebola cases is waning in West Africa. Officials from the United States Department of Health and Human Services said that could make it harder to determine if either of the vaccines [were] preventing disease. More participants may have to be added to the trial, or it may need to be expanded to neighboring Sierra Leone, they said…” (Pollack, 1/23).
Reuters: First GSK Ebola vaccine shipment due to arrive in Liberia
“…Researchers hope eventually to enroll up to 30,000 people in the trial, a third of whom would get GSK’s candidate vaccine…” (Kelland, 1/23).